{"protocolSection":{"identificationModule":{"nctId":"NCT04865770","orgStudyIdInfo":{"id":"NN9535-4662"},"secondaryIdInfos":[{"id":"U1111-1248-7912","type":"OTHER","domain":"World Health Organization (WHO)"},{"id":"2020-000828-19","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Novo Nordisk A/S","class":"INDUSTRY"},"briefTitle":"A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)","officialTitle":"Renal Mode of Action of Semaglutide in Patients With Type 2 Diabetes and Chronic Kidney Disease","acronym":"REMODEL"},"statusModule":{"statusVerifiedDate":"2026-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-04-28","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-11-21","type":"ACTUAL"},"completionDateStruct":{"date":"2024-11-21","type":"ACTUAL"},"studyFirstSubmitDate":"2021-04-26","studyFirstSubmitQcDate":"2021-04-26","studyFirstPostDateStruct":{"date":"2021-04-29","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-11-20","resultsFirstSubmitQcDate":"2025-12-21","resultsFirstPostDateStruct":{"date":"2026-01-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-02-09","lastUpdatePostDateStruct":{"date":"2026-02-10","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novo Nordisk A/S","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys.\n\nParticipants will either get semaglutide or placebo (a 'dummy' medicine) - which treatment participants get is decided by chance.\n\nSemaglutide is a medicine doctors can prescribe in some countries for the treatment of type 2 diabetes.\n\nParticipants will get the study medicine in a pen. Participants will use the pen to inject the medicine into the skin once a week.\n\nThe study will last for about 1 year. Participants will have 11 visits to the clinic, and 2 phone visits. Some of the visits could be in different locations.\n\nStudy staff will take blood samples at most of these visits. At 9 visits, participants will be asked to bring a sample of their first morning urine. At 4 of the visits participants will have to bring urine that they have collected over the last 24 hours.\n\nThe study includes magnetic resonance imaging (MRI) scans of participants' kidneys which is a test that shows a detailed picture of organs and other parts inside the body. The scan will last for 30 minutes, and is free of radiation."},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2","Chronic Kidney Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"Sponsor staff involved in the clinical trial is masked according to company standard procedures.","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":106,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Semaglutide 1.0 mg OW","type":"EXPERIMENTAL","description":"Once-weekly (OW) Semaglutide administered subcutaneously (s.c., under the skin).","interventionNames":["Drug: Semaglutide"]},{"label":"Placebo (Semaglutide) 1.0 mg OW","type":"PLACEBO_COMPARATOR","description":"Once-weekly (OW) placebo (Semaglutide) administered subcutaneously (s.c., under the skin).","interventionNames":["Drug: Placebo (Semaglutide)"]}],"interventions":[{"type":"DRUG","name":"Semaglutide","description":"Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.","armGroupLabels":["Semaglutide 1.0 mg OW"]},{"type":"DRUG","name":"Placebo (Semaglutide)","description":"Placebo (Semaglutide) given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.","armGroupLabels":["Placebo (Semaglutide) 1.0 mg OW"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*)","description":"Change in kidney oxygenation in cortex assessed by BOLD (blood oxygenation level dependent) MRI from baseline (week 0) to end of treatment (week 52) is presented. R2\\* is a measure used in BOLD MRI to indicate the level of tissue oxygenation. A higher R2\\* value means lower tissue oxygenation while a lower R2\\* value means higher tissue oxygenation.","timeFrame":"Baseline (week 0), End of treatment (week 52)"},{"measure":"Change in Kidney Oxygenation (Medulla), BOLD MRI (R2*)","description":"Change in kidney oxygenation in medulla assessed by BOLD (blood oxygenation level dependent) MRI from baseline (week 0) to end of treatment (week 52) is presented. R2\\* is a measure used in BOLD MRI to indicate the level of tissue oxygenation. A higher R2\\* value means lower tissue oxygenation while a lower R2\\* value means higher tissue oxygenation.","timeFrame":"Baseline (week 0), End of treatment (week 52)"},{"measure":"Change in Global Kidney Perfusion (MRI)","description":"Change in global kidney perfusion assessed by phase contrast MRI from baseline (week 0) to end of treatment (week 52) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 52)"},{"measure":"Change in Kidney Inflammation (Cortex), Longitudinal Relaxation Time (T1) Mapping (MRI)","description":"Change in kidney inflammation in cortex assessed by T1 mapping MRI from baseline (week 0) to end of treatment (week 52) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 52)"},{"measure":"Change in Kidney Inflammation (Medulla), T1 Mapping (MRI)","description":"Change in kidney inflammation in medulla assessed by T1 mapping MRI from baseline (week 0) to end of treatment (week 52) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 52)"}],"secondaryOutcomes":[{"measure":"Change in Gene Expression Assessed by Single Nucleus Ribonucleic Acid (RNA) Sequencing (Kidney Biopsy)","description":"Changes in gene expression were assessed by single nucleus RNA sequencing (kidney biopsies) from baseline (week 0) to end of treatment (week 52). Cell type annotation was performed prior to the analysis. The analysis reports the log2 fold change in form of differential gene expression per cell type from baseline, comparing treatment arms. Genes are considered significant if fold change \\> 0.5 or \\< 0.5 and false discovery rate (FDR) \\<0.1; these criteria help identify biologically significant genes that are reliably differentially expressed in patients with conditions such as Type 2 diabetes and chronic kidney disease. The differential expression was estimated using a linear mixed model that included participant as a random effect. The cell types presented are those that contain these differentially expressed genes demonstrating the treatment response. This threshold is based on findings published in cross-sectional observational studies related to disease impact and gene activity.","timeFrame":"Baseline (week 0), End of treatment (week 52)"},{"measure":"Change in Glomerular Basement Membrane Width (Kidney Biopsy)","description":"Change in glomerular basement membrane width assessed in kidney biopsy from baseline (week 0) to end of treatment (week 52) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 52)"},{"measure":"Change in Apparent Diffusion Coefficient (ADC) (Cortex) (MRI)","description":"Change in apparent diffusion coefficient in cortex assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 52)"},{"measure":"Change in Apparent Diffusion Coefficient (ADC) (Medulla) (MRI)","description":"Change in apparent diffusion coefficient in medulla assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 52)"},{"measure":"Change in Mean Renal Artery Resistive Index (RARI) (MRI)","description":"Change in renal arterial resistive index assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented. RARI measures the preservation of blood flow in renal arteries throughout the cardiac cycle and is therefore a measure for resistance of blood flow within the renal arteries. It serves as an indicator of kidney vascular health and potential arterial stiffness or obstruction. It is prognostic for primary cardiovascular and renal events in type 2 diabetes, where a lower RARI predicts a lower rate of events. RARI is calculated by relating the difference between blood flow at maximum velocity during the cardiac contraction phase (peak systolic velocity, PSV) and the speed at the end of the relaxation phase, at the point of minimal velocity (end diastolic velocity, EDV) with PSV, i.e., RARI = (PSV-EDV)/PSV.","timeFrame":"Baseline (week 0), End of treatment (week 52)"},{"measure":"Change in Mean Arterial Flow (MRI)","description":"Change in mean arterial flow assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 52)"},{"measure":"Change in Natriuresis (Urinary Sodium Excretion) (Urinalysis)","description":"Change in natriuresis (urinary sodium excretion) (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 52)"},{"measure":"Change in Albumin Excretion Rate (Urinalysis)","description":"Change in albumin excretion rate (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 52)"},{"measure":"Change in Kidney Function (Creatinine Clearance) (Urinalysis)","description":"Change in kidney function (creatinine clearance) (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.","timeFrame":"Baseline (week 0), End of treatment (week 52)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female.\n* Age above or equal to 18 years at the time of signing informed consent.\n* Diagnosed with T2D (type 2 diabetes) greater than or equal to 180 days prior to the day of screening.\n* HbA1c (glycated haemoglobin) below or equal to 9.0 percent (below or equal to 75 mmol/mol).\n* Depending on biopsy/non-biopsy population:\n\n  1. For subjects in the non-biopsy population: Serum creatinine-based eGFR greater than or equal to 30 and below or equal to 75 mL/min/1.73 m\\^2(CKD-EPI).\n  2. For subjects in the biopsy sub-population: Serum creatinine-based eGFR greater than or equal to 40 and below or equal to 75 mL/min/1.73 m\\^2(CKD-EPI).\n* UACR ( Urinary albumin-to-creatinine ratio ) greater than or equal to 20 and below 5000 mg/g.\n* Treatment with maximum labelled or tolerated dose of a renin-angiotensin-aldosterone system (RAAS) blocking agent including an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB)) unless such treatment is contraindicated or not tolerated.Treatment dose must be stable for at least 28 days prior to screening.\n\nExclusion Criteria:\n\n* Use of any glucagon-like peptide 1 receptor agonist (GLP-1 RA) within 30 days prior to screening.\n* A prior solid organ transplant or awaiting solid organ transplant.\n* Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within 180 days prior to the day of screening.\n* Presence or history of malignant neoplasms (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) within 5 years prior to the day of screening.\n* Congenital or hereditary kidney diseases including polycystic kidney disease, autoimmune kidney diseases including glomerulonephritis or congenital urinary tract malformations.\n* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and Visit 2. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.\n* Treatment with systemic anti-inflammatory or immunosuppressant drugs within 90 days prior to screening. Stable treatment with acetylsalicylic acid for prevention of cardiovascular events and occasional use of propionic acid derivatives drugs (e.g. ibuprofen) is allowed.\n* Any contraindication for MRI according to standard checklist used in clinical routine, including claustrophobia or metallic foreign bodies, metallic implants, internal electrical devices, or permanent makeup/tattoos that cannot be declared MR compatible.\n* Combination use of an ACE (angiotensin-converting enzyme) inhibitor and an ARB (angiotensin II receptor blockers).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Transparency (Dept.2834)","affiliation":"Novo Nordisk A/S","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"University of Arizona-CaTs","city":"Tucson","state":"Arizona","zip":"85724","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"Academic Medical Research Institute","city":"Los Angeles","state":"California","zip":"90022","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Roderick A. Comunale II MD Inc.","city":"National City","state":"California","zip":"91950","country":"United States","geoPoint":{"lat":32.67811,"lon":-117.0992}},{"facility":"N America Res Inst - San Dimas","city":"San Dimas","state":"California","zip":"91773","country":"United States","geoPoint":{"lat":34.10668,"lon":-117.80673}},{"facility":"UC Anschutz Medical Campus","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"Advent Health-Res Inst","city":"Orlando","state":"Florida","zip":"32804","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Atlanta Diabetes Associates","city":"Atlanta","state":"Georgia","zip":"30318","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Emory University Hsptl - Atlanta","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Endeavor Health Glenbook Hosp","city":"Evanston","state":"Illinois","zip":"60201","country":"United States","geoPoint":{"lat":42.04114,"lon":-87.69006}},{"facility":"North Suburban Nephrology LLC","city":"Gurnee","state":"Illinois","zip":"60031","country":"United States","geoPoint":{"lat":42.3703,"lon":-87.90202}},{"facility":"University of Minnesota Health Clinical","city":"Minneapolis","state":"Minnesota","zip":"55455","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"Clinical Research Consultants, LLC","city":"Kansas City","state":"Missouri","zip":"64111","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Cleveland Clinic_Cleveland","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Prolato Clinical Research Cntr","city":"Houston","state":"Texas","zip":"77054","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Sun Research Institute","city":"San Antonio","state":"Texas","zip":"78215","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"NE Clin Res of San Antonio","city":"San Antonio","state":"Texas","zip":"78233","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"University of Texas San Antonio","city":"San Antonio","state":"Texas","zip":"78284","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Univ of Washington Med Ctr","city":"Seattle","state":"Washington","zip":"98195","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Providence Medical Research Center","city":"Spokane","state":"Washington","zip":"99204","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"Medical College Of Wisconsin","city":"Milwaukee","state":"Wisconsin","zip":"53226","country":"United States","geoPoint":{"lat":43.0389,"lon":-87.90647}},{"facility":"LMC ClinRsrh Inc.Brampton","city":"Brampton","state":"Ontario","zip":"L6S 0C6","country":"Canada","geoPoint":{"lat":43.68341,"lon":-79.76633}},{"facility":"UHN-Toronto General Hospital","city":"Toronto","state":"Ontario","zip":"M5G 2N2","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Nefrologisk Klinik P 2132","city":"Copenhagen","zip":"2100","country":"Denmark","geoPoint":{"lat":55.67594,"lon":12.56553}},{"facility":"Rigshospitalet - Nefrologisk Klinik P 2132","city":"Copenhagen","zip":"2100","country":"Denmark","geoPoint":{"lat":55.67594,"lon":12.56553}},{"facility":"Steno Diabetes Center Copenhagen","city":"Herlev","zip":"2730","country":"Denmark","geoPoint":{"lat":55.72366,"lon":12.43998}},{"facility":"Centre Hospitalier Universitaire Amiens Picardie-Site Sud","city":"Amiens","zip":"80054","country":"France","geoPoint":{"lat":49.9,"lon":2.3}},{"facility":"Centre Hospitalier Universitaire de Rouen - Hopital de Bois Guillaume","city":"Bois-Guillaume","zip":"76230","country":"France","geoPoint":{"lat":49.4602,"lon":1.12219}},{"facility":"Centre Hospitalier Universitaire Grenoble Alpes-Site Nord Michallon-2","city":"Grenoble - Cédex 09","zip":"38043","country":"France"},{"facility":"Les Hopitaux de Chartres-Hopital Louis Pasteur","city":"Le Coudray","zip":"28630","country":"France","geoPoint":{"lat":48.42115,"lon":1.50057}},{"facility":"Chu de Reims-Hopital Maison Blanche","city":"Reims","zip":"51092","country":"France","geoPoint":{"lat":49.26526,"lon":4.02853}},{"facility":"Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil","city":"Toulouse","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Istituto Scientifico San Raffaele","city":"Milan","state":"MI","zip":"20132","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Azienda Ospedaliera Papa Giovanni XXIII","city":"Bergamo","zip":"24127","country":"Italy","geoPoint":{"lat":45.69601,"lon":9.66721}},{"facility":"Azienda Ospedaliera di Padova Clin.Med.3","city":"Padova","zip":"35128","country":"Italy","geoPoint":{"lat":44.38225,"lon":11.14261}},{"facility":"Presidio Ospedaliero Cisanello","city":"Pisa","zip":"56124","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"facility":"Azienda Ospedaliero - Universitaria Sant'Andrea","city":"Roma","zip":"00189","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"facility":"In-Vivo Sp. z o.o.","city":"Bydgoszcz","zip":"85-048","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Centrum Medyczne \"Diabetika\"","city":"Radom","zip":"26-600","country":"Poland","geoPoint":{"lat":51.40253,"lon":21.14714}},{"facility":"Uniwersytecki Szpital Kliniczny Nr 2 PUM W Szczecinie","city":"Szczecin","zip":"70-111","country":"Poland","geoPoint":{"lat":53.42894,"lon":14.55302}},{"facility":"Miedzyleski Szpital Specjalistyczny, Oddzial Nefrologiczny","city":"Warsaw","zip":"04-749","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Prywatny Gabinet Janusz Gumprecht","city":"Zabrze","zip":"41-800","country":"Poland","geoPoint":{"lat":50.32492,"lon":18.78576}},{"facility":"Maxwell Centre","city":"Durban","state":"KwaZulu-Natal","zip":"4001","country":"South Africa","geoPoint":{"lat":-29.8579,"lon":31.0292}},{"facility":"Precise Clinical Solutions (Pty) Ltd","city":"Durban","state":"KwaZulu-Natal","zip":"4092","country":"South Africa","geoPoint":{"lat":-29.8579,"lon":31.0292}},{"facility":"Lenmed Shifa Private Hospital","city":"Durban","state":"KwaZulu-Natal","zip":"4901","country":"South Africa","geoPoint":{"lat":-29.8579,"lon":31.0292}},{"facility":"Prof Rayner_Division of Nephrology","city":"Cape Town","state":"Western Cape","zip":"7925","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"facility":"Hospital Vall d'Hebron","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital de Bellvitge","city":"L'Hospitalet de Llobregat","zip":"08907","country":"Spain","geoPoint":{"lat":41.35967,"lon":2.10028}},{"facility":"Hospital Clinico Universitario de Valencia","city":"Valencia","zip":"46010","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Hospital Clínico Universitario de Valencia","city":"Valencia","zip":"46010","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}}]},"referencesModule":{"references":[{"pmid":"42823485","type":"DERIVED","citation":"Tuttle KR, Bjornstad P, Smith C, Pruijm M, McCown PJ, Hodgin JB, Cherney DZI, Belmar N, Chacko MM, Das V, Gunnarsson TP, Idorn T, Schytz PA, Zaratiegui A, Kretzler M. Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial. Nat Med. 2026 Oct 1. doi: 10.1038/s41591-026-04674-2. Online ahead of print."},{"pmid":"41207620","type":"DERIVED","citation":"Pruijm M, Belmar N, Bjornstad P, Cherney DZI, Das V, Gunnarsson T, Hodgin JB, Schytz PA, Tuttle KR, Kretzler M. REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide. Kidney Int. 2026 Jan;109(1):6-16. doi: 10.1016/j.kint.2025.10.005. Epub 2025 Nov 7."},{"pmid":"39963952","type":"DERIVED","citation":"Natale P, Green SC, Tunnicliffe DJ, Pellegrino G, Toyama T, Strippoli GF. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2."},{"pmid":"39480988","type":"DERIVED","citation":"Mendonca L, Moura H, Chaves PC, Neves JS, Ferreira JP. The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes: A Meta-Analysis of Randomized Placebo-Controlled Trials. Clin J Am Soc Nephrol. 2025 Feb 1;20(2):159-168. doi: 10.2215/CJN.0000000584. Epub 2024 Oct 8."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"According to the Novo Nordisk disclosure commitment on novonordisk-trials.com","url":"http://novonordisk-trials.com"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Participants were randomized in a 2:1 ratio to receive semaglutide or placebo, respectively. Both added to standard-of-care treatment.","recruitmentDetails":"The trial was conducted at 31 sites in 8 countries.","groups":[{"id":"FG000","title":"Semaglutide 1.0 mg","description":"Participants received once-weekly (OW) subcutaneous (s. c.) injection of semaglutide for 52 weeks. Participants received a dose of 0.25 milligrams (mg) from week 0 to week 4, then the dose was increased to 0.5 mg from week 4 to week 8. From week 8 to week 52, the dosage was 1.0 mg."},{"id":"FG001","title":"Placebo","description":"Participants received once-weekly (OW) subcutaneous injection (s. c.) of placebo matched for semaglutide for 52 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"71"},{"groupId":"FG001","numSubjects":"35"}]},{"type":"Full Analysis Set","achievements":[{"groupId":"FG000","numSubjects":"71"},{"groupId":"FG001","numSubjects":"35"}]},{"type":"Safety Analysis Set","achievements":[{"groupId":"FG000","numSubjects":"71"},{"groupId":"FG001","numSubjects":"35"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"34"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Full analysis set included all participants randomly assigned to trial treatment and who took at least 1 dose of trial product.","groups":[{"id":"BG000","title":"Semaglutide 1.0 mg","description":"Participants received once-weekly (OW) subcutaneous (s. c.) injection of semaglutide for 52 weeks. Participants received a dose of 0.25 milligrams (mg) from week 0 to week 4, then the dose was increased to 0.5 mg from week 4 to week 8. From week 8 to week 52, the dosage was 1.0 mg."},{"id":"BG001","title":"Placebo","description":"Participants received once-weekly (OW) subcutaneous injection (s. c.) of placebo matched for semaglutide for 52 weeks."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"71"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"106"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"65.4","spread":"9.2"},{"groupId":"BG001","value":"65.1","spread":"11.3"},{"groupId":"BG002","value":"65.3","spread":"9.9"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"25"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"81"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"87"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"11"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian Or Alaska Native","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]},{"title":"Black Or African American","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"10"}]},{"title":"Not Reported","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"10"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"65"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"15"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*)","description":"Change in kidney oxygenation in cortex assessed by BOLD (blood oxygenation level dependent) MRI from baseline (week 0) to end of treatment (week 52) is presented. R2\\* is a measure used in BOLD MRI to indicate the level of tissue oxygenation. A higher R2\\* value means lower tissue oxygenation while a lower R2\\* value means higher tissue oxygenation.","populationDescription":"Full analysis set included all participants randomly assigned to trial treatment and who took at least 1 dose of trial product. Overall number of participants analyzed= FAS. Number Analyzed= number of participants with available data for particular timepoint, for the respective arms.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of kidney oxygenation (cortex)","timeFrame":"Baseline (week 0), End of treatment (week 52)","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Participants received once-weekly (OW) subcutaneous (s. c.) injection of semaglutide for 52 weeks. Participants received a dose of 0.25 milligrams (mg) from week 0 to week 4, then the dose was increased to 0.5 mg from week 4 to week 8. From week 8 to week 52, the dosage was 1.0 mg."},{"id":"OG001","title":"Placebo","description":"Participants received once-weekly (OW) subcutaneous injection (s. c.) of placebo matched for semaglutide for 52 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"35"}]}],"classes":[{"title":"Bilateral cortex","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"5.35"},{"groupId":"OG001","value":"1.00","spread":"7.39"}]}]},{"title":"Right cortex","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"5.65"},{"groupId":"OG001","value":"0.99","spread":"7.26"}]}]},{"title":"Left cortex","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"7.51"},{"groupId":"OG001","value":"1.01","spread":"9.12"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Bilateral cortex: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate, on log scale.","nonInferiorityType":"OTHER","pValue":"0.1333","statisticalMethod":"ANCOVA","paramType":"Treatment ratio","paramValue":"0.98","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.96","ciUpperLimit":"1.01"},{"groupIds":["OG000","OG001"],"groupDescription":"Right cortex: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate, on log scale.","nonInferiorityType":"OTHER","pValue":"0.2487","statisticalMethod":"ANCOVA","paramType":"Treatment ratio","paramValue":"0.99","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.96","ciUpperLimit":"1.01"},{"groupIds":["OG000","OG001"],"groupDescription":"Left cortex: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate, on log scale.","nonInferiorityType":"OTHER","pValue":"0.0907","statisticalMethod":"ANCOVA","paramType":"Treatment ratio","paramValue":"0.97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.94","ciUpperLimit":"1.00"}]},{"type":"PRIMARY","title":"Change in Kidney Oxygenation (Medulla), BOLD MRI (R2*)","description":"Change in kidney oxygenation in medulla assessed by BOLD (blood oxygenation level dependent) MRI from baseline (week 0) to end of treatment (week 52) is presented. R2\\* is a measure used in BOLD MRI to indicate the level of tissue oxygenation. A higher R2\\* value means lower tissue oxygenation while a lower R2\\* value means higher tissue oxygenation.","populationDescription":"Full analysis set included all participants randomly assigned to trial treatment and who took at least 1 dose of trial product. Overall number of participants analyzed= FAS. Number Analyzed= number of participants with available data for particular timepoint, for the respective arms.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of kidney oxygenation (medulla)","timeFrame":"Baseline (week 0), End of treatment (week 52)","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Participants received once-weekly (OW) subcutaneous (s. c.) injection of semaglutide for 52 weeks. Participants received a dose of 0.25 milligrams (mg) from week 0 to week 4, then the dose was increased to 0.5 mg from week 4 to week 8. From week 8 to week 52, the dosage was 1.0 mg."},{"id":"OG001","title":"Placebo","description":"Participants received once-weekly (OW) subcutaneous injection (s. c.) of placebo matched for semaglutide for 52 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"35"}]}],"classes":[{"title":"Bilateral medulla","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"8.97"},{"groupId":"OG001","value":"1.01","spread":"11.37"}]}]},{"title":"Right medulla","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"10.09"},{"groupId":"OG001","value":"1.02","spread":"10.83"}]}]},{"title":"Left medulla","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"10.25"},{"groupId":"OG001","value":"1.02","spread":"13.02"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Bilateral medulla: The responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.","nonInferiorityType":"OTHER","pValue":"0.5619","statisticalMethod":"ANCOVA","paramType":"Treatment ratio","paramValue":"0.99","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.94","ciUpperLimit":"1.03"},{"groupIds":["OG000","OG001"],"groupDescription":"Right medulla: The responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.","nonInferiorityType":"OTHER","pValue":"0.2774","statisticalMethod":"ANCOVA","paramType":"Treatment ratio","paramValue":"0.97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.93","ciUpperLimit":"1.02"},{"groupIds":["OG000","OG001"],"groupDescription":"Left medulla: The responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.","nonInferiorityType":"OTHER","pValue":"0.7924","statisticalMethod":"ANCOVA","paramType":"Treatment ratio","paramValue":"0.99","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.94","ciUpperLimit":"1.04"}]},{"type":"PRIMARY","title":"Change in Global Kidney Perfusion (MRI)","description":"Change in global kidney perfusion assessed by phase contrast MRI from baseline (week 0) to end of treatment (week 52) is presented.","populationDescription":"Full analysis set included all participants randomly assigned to trial treatment and who took at least 1 dose of trial product. Overall number of participants analyzed= FAS. Number Analyzed= number of participants with available data for particular timepoint, for the respective arms.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of global kidney perfusion","timeFrame":"Baseline (week 0), End of treatment (week 52)","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Participants received once-weekly (OW) subcutaneous (s. c.) injection of semaglutide for 52 weeks. Participants received a dose of 0.25 milligrams (mg) from week 0 to week 4, then the dose was increased to 0.5 mg from week 4 to week 8. From week 8 to week 52, the dosage was 1.0 mg."},{"id":"OG001","title":"Placebo","description":"Participants received once-weekly (OW) subcutaneous injection (s. c.) of placebo matched for semaglutide for 52 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"35"}]}],"classes":[{"title":"Bilateral kidney","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":"26.43"},{"groupId":"OG001","value":"0.99","spread":"24.39"}]}]},{"title":"Right kidney","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":"27.84"},{"groupId":"OG001","value":"0.98","spread":"28.85"}]}]},{"title":"Left kidney","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","spread":"29.25"},{"groupId":"OG001","value":"1.01","spread":"26.83"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Bilateral kidney: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.","nonInferiorityType":"OTHER","pValue":"0.0958","statisticalMethod":"ANCOVA","paramType":"Treatment ratio","paramValue":"1.10","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.98","ciUpperLimit":"1.24"},{"groupIds":["OG000","OG001"],"groupDescription":"Right kidney: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.","nonInferiorityType":"OTHER","pValue":"0.0145","statisticalMethod":"ANCOVA","paramType":"Treatment ratio","paramValue":"1.17","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.03","ciUpperLimit":"1.33"},{"groupIds":["OG000","OG001"],"groupDescription":"Left kidney: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.","nonInferiorityType":"OTHER","pValue":"0.3311","statisticalMethod":"ANCOVA","paramType":"Treatment ratio","paramValue":"1.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.94","ciUpperLimit":"1.21"}]},{"type":"PRIMARY","title":"Change in Kidney Inflammation (Cortex), Longitudinal Relaxation Time (T1) Mapping (MRI)","description":"Change in kidney inflammation in cortex assessed by T1 mapping MRI from baseline (week 0) to end of treatment (week 52) is presented.","populationDescription":"Full analysis set included all participants randomly assigned to trial treatment and who took at least 1 dose of trial product. Overall number of participants analyzed= FAS. Number Analyzed= number of participants with available data for particular timepoint, for the respective arms.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of kidney inflammation (cortex)","timeFrame":"Baseline (week 0), End of treatment (week 52)","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Participants received once-weekly (OW) subcutaneous (s. c.) injection of semaglutide for 52 weeks. Participants received a dose of 0.25 milligrams (mg) from week 0 to week 4, then the dose was increased to 0.5 mg from week 4 to week 8. From week 8 to week 52, the dosage was 1.0 mg."},{"id":"OG001","title":"Placebo","description":"Participants received once-weekly (OW) subcutaneous injection (s. c.) of placebo matched for semaglutide for 52 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"35"}]}],"classes":[{"title":"Bilateral cortex","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"3.78"},{"groupId":"OG001","value":"1.01","spread":"5.43"}]}]},{"title":"Right cortex","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"3.88"},{"groupId":"OG001","value":"1.01","spread":"5.57"}]}]},{"title":"Left cortex","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"3.93"},{"groupId":"OG001","value":"1.01","spread":"5.71"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Bilateral cortex: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.","nonInferiorityType":"OTHER","pValue":"0.8651","statisticalMethod":"ANCOVA","paramType":"Treatment ratio","paramValue":"1.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.98","ciUpperLimit":"1.02"},{"groupIds":["OG000","OG001"],"groupDescription":"Right cortex: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.","nonInferiorityType":"OTHER","pValue":"0.7240","statisticalMethod":"ANCOVA","paramType":"Treatment ratio","paramValue":"1.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.98","ciUpperLimit":"1.02"},{"groupIds":["OG000","OG001"],"groupDescription":"Left cortex: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.","nonInferiorityType":"OTHER","pValue":"0.7195","statisticalMethod":"ANCOVA","paramType":"Treatment ratio","paramValue":"1.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.98","ciUpperLimit":"1.02"}]},{"type":"PRIMARY","title":"Change in Kidney Inflammation (Medulla), T1 Mapping (MRI)","description":"Change in kidney inflammation in medulla assessed by T1 mapping MRI from baseline (week 0) to end of treatment (week 52) is presented.","populationDescription":"Full analysis set included all participants randomly assigned to trial treatment and who took at least 1 dose of trial product. Overall number of participants analyzed= FAS. Number Analyzed= number of participants with available data for particular timepoint, for the respective arms.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of kidney inflammation (medulla)","timeFrame":"Baseline (week 0), End of treatment (week 52)","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Participants received once-weekly (OW) subcutaneous (s. c.) injection of semaglutide for 52 weeks. Participants received a dose of 0.25 milligrams (mg) from week 0 to week 4, then the dose was increased to 0.5 mg from week 4 to week 8. From week 8 to week 52, the dosage was 1.0 mg."},{"id":"OG001","title":"Placebo","description":"Participants received once-weekly (OW) subcutaneous injection (s. c.) of placebo matched for semaglutide for 52 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"35"}]}],"classes":[{"title":"Bilateral medulla","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"3.56"},{"groupId":"OG001","value":"1.00","spread":"5.13"}]}]},{"title":"Right medulla","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"3.90"},{"groupId":"OG001","value":"1.01","spread":"4.85"}]}]},{"title":"Left medulla","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"3.69"},{"groupId":"OG001","value":"1.00","spread":"5.91"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Bilateral medulla: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.","nonInferiorityType":"OTHER","pValue":"0.9335","statisticalMethod":"ANCOVA","paramType":"Treatment ratio","paramValue":"1.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.98","ciUpperLimit":"1.02"},{"groupIds":["OG000","OG001"],"groupDescription":"Right medulla: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.","nonInferiorityType":"OTHER","pValue":"0.6517","statisticalMethod":"ANCOVA","paramType":"Treatment ratio","paramValue":"1.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.98","ciUpperLimit":"1.01"},{"groupIds":["OG000","OG001"],"groupDescription":"Left medulla: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.","nonInferiorityType":"OTHER","pValue":"0.9017","statisticalMethod":"ANCOVA","paramType":"Treatment ratio","paramValue":"1.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.98","ciUpperLimit":"1.02"}]},{"type":"SECONDARY","title":"Change in Gene Expression Assessed by Single Nucleus Ribonucleic Acid (RNA) Sequencing (Kidney Biopsy)","description":"Changes in gene expression were assessed by single nucleus RNA sequencing (kidney biopsies) from baseline (week 0) to end of treatment (week 52). Cell type annotation was performed prior to the analysis. The analysis reports the log2 fold change in form of differential gene expression per cell type from baseline, comparing treatment arms. Genes are considered significant if fold change \\> 0.5 or \\< 0.5 and false discovery rate (FDR) \\<0.1; these criteria help identify biologically significant genes that are reliably differentially expressed in patients with conditions such as Type 2 diabetes and chronic kidney disease. The differential expression was estimated using a linear mixed model that included participant as a random effect. The cell types presented are those that contain these differentially expressed genes demonstrating the treatment response. This threshold is based on findings published in cross-sectional observational studies related to disease impact and gene activity.","populationDescription":"Full analysis set included all participants randomly assigned to trial treatment and who took at least 1 dose of trial product. Overall Number participants analyzed = number of participants with available data for particular timepoint, for the respective arms.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"log2 fold-change","timeFrame":"Baseline (week 0), End of treatment (week 52)","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg/Placebo","description":"Participants received OW treatment with 0.25 mg semaglutide or placebo from week 0 to week 4 followed by 0.5 mg semaglutide or placebo from week 4 to week 8 followed by 1 mg semaglutide or placebo from week 8 to week 52 depending on the arm they were randomised to. This arm has combined data from Semaglutide arm and Placebo arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"classes":[{"title":"CNT-2, RSPO3","categories":[{"measurements":[{"groupId":"OG000","value":"3.468216523"}]}]},{"title":"CNT-Immune, SLC8A1-AS1","categories":[{"measurements":[{"groupId":"OG000","value":"2.8531071"}]}]},{"title":"EC-GC-1, KCNK6","categories":[{"measurements":[{"groupId":"OG000","value":"-1.952545192"}]}]},{"title":"EC-GC-1, EMC10","categories":[{"measurements":[{"groupId":"OG000","value":"-2.485824696"}]}]},{"title":"EC-GC-1, ENSG00000286145","categories":[{"measurements":[{"groupId":"OG000","value":"1.831300888"}]}]},{"title":"EC-GC-1, LMF1","categories":[{"measurements":[{"groupId":"OG000","value":"-1.528463786"}]}]},{"title":"EC-GC-1, ANKUB1","categories":[{"measurements":[{"groupId":"OG000","value":"1.783402404"}]}]},{"title":"EC-GC-1, AHNAK","categories":[{"measurements":[{"groupId":"OG000","value":"-1.368952211"}]}]},{"title":"EC-GC-1, ENSG00000286150","categories":[{"measurements":[{"groupId":"OG000","value":"1.318309657"}]}]},{"title":"EC-GC-1, NSUN6","categories":[{"measurements":[{"groupId":"OG000","value":"-1.464540152"}]}]},{"title":"EC-GC-1, TFCP2L1","categories":[{"measurements":[{"groupId":"OG000","value":"-2.24516792"}]}]},{"title":"EC-GC-1, ENSG00000274422","categories":[{"measurements":[{"groupId":"OG000","value":"-1.860725608"}]}]},{"title":"EC-GC-1, DPYD-AS1","categories":[{"measurements":[{"groupId":"OG000","value":"1.996950045"}]}]},{"title":"EC-GC-1, ENSG00000248138","categories":[{"measurements":[{"groupId":"OG000","value":"2.110414741"}]}]},{"title":"EC-GC-1, ACSM2B","categories":[{"measurements":[{"groupId":"OG000","value":"-1.785467699"}]}]},{"title":"EC-GC-1, CCNH","categories":[{"measurements":[{"groupId":"OG000","value":"1.033873239"}]}]},{"title":"EC-GC-1, QTRT1","categories":[{"measurements":[{"groupId":"OG000","value":"-2.415240141"}]}]},{"title":"EC-GC-1, CROCCP3","categories":[{"measurements":[{"groupId":"OG000","value":"-1.254541813"}]}]},{"title":"EC-GC-1, ENSG00000251034","categories":[{"measurements":[{"groupId":"OG000","value":"1.750285729"}]}]},{"title":"EC-GC-1, LSAMP","categories":[{"measurements":[{"groupId":"OG000","value":"-2.439268964"}]}]},{"title":"EC-GC-1, LHX1-DT","categories":[{"measurements":[{"groupId":"OG000","value":"-4.256689925"}]}]},{"title":"EC-GC-1, ESRRG","categories":[{"measurements":[{"groupId":"OG000","value":"-1.527414037"}]}]},{"title":"EC-GC-1, CNTNAP2","categories":[{"measurements":[{"groupId":"OG000","value":"-2.377391827"}]}]},{"title":"EC-GC-1, ENSG00000284966","categories":[{"measurements":[{"groupId":"OG000","value":"1.665764749"}]}]},{"title":"EC-GC-1, BICC1","categories":[{"measurements":[{"groupId":"OG000","value":"-1.445239386"}]}]},{"title":"EC-GC-1, GNA14-AS1","categories":[{"measurements":[{"groupId":"OG000","value":"1.192645521"}]}]},{"title":"EC-GC-1, GUSBP11","categories":[{"measurements":[{"groupId":"OG000","value":"-1.318511642"}]}]},{"title":"EC-GC-1, ENSG00000233783","categories":[{"measurements":[{"groupId":"OG000","value":"1.668536087"}]}]},{"title":"EC-GC-1, SEMA6A-AS1","categories":[{"measurements":[{"groupId":"OG000","value":"1.183886707"}]}]},{"title":"EC-GC-1, RBMS3-AS2","categories":[{"measurements":[{"groupId":"OG000","value":"1.572052032"}]}]},{"title":"EC-GC-1, ENSG00000286147","categories":[{"measurements":[{"groupId":"OG000","value":"-4.468841041"}]}]},{"title":"EC-GC-1, LINC00342","categories":[{"measurements":[{"groupId":"OG000","value":"-1.151143461"}]}]},{"title":"EC-GC-1, IRF3","categories":[{"measurements":[{"groupId":"OG000","value":"-1.566408786"}]}]},{"title":"EC-GC-1, ENSG00000249207","categories":[{"measurements":[{"groupId":"OG000","value":"1.35685803"}]}]},{"title":"EC-GC-1, CRADD-AS1","categories":[{"measurements":[{"groupId":"OG000","value":"1.972404772"}]}]},{"title":"EC-GC-1, TOX3","categories":[{"measurements":[{"groupId":"OG000","value":"-2.206055055"}]}]},{"title":"EC-GC-1, ENSG00000286458","categories":[{"measurements":[{"groupId":"OG000","value":"1.271036656"}]}]},{"title":"EC-GC-1, SLC12A3","categories":[{"measurements":[{"groupId":"OG000","value":"-2.531722898"}]}]},{"title":"EC-GC-1, TALAM1","categories":[{"measurements":[{"groupId":"OG000","value":"1.235573321"}]}]},{"title":"EC-GC-1, PCDH17","categories":[{"measurements":[{"groupId":"OG000","value":"1.107442597"}]}]},{"title":"EC-GC-1, ATP13A3","categories":[{"measurements":[{"groupId":"OG000","value":"1.078246118"}]}]},{"title":"EC-GC-1, ENSG00000231772","categories":[{"measurements":[{"groupId":"OG000","value":"-2.382264501"}]}]},{"title":"EC-GC-1, FBXL19","categories":[{"measurements":[{"groupId":"OG000","value":"-2.166973377"}]}]},{"title":"EC-GC-1, ENSG00000254420","categories":[{"measurements":[{"groupId":"OG000","value":"1.74612131"}]}]},{"title":"EC-GC-1, SPC25","categories":[{"measurements":[{"groupId":"OG000","value":"1.329461228"}]}]},{"title":"EC-GC-1, SMAD4","categories":[{"measurements":[{"groupId":"OG000","value":"1.13655744"}]}]},{"title":"EC-GC-1, UFM1","categories":[{"measurements":[{"groupId":"OG000","value":"1.20264148"}]}]},{"title":"EC-GC-1, ENSG00000259564","categories":[{"measurements":[{"groupId":"OG000","value":"2.071724947"}]}]},{"title":"EC-GC-1, SHOC1","categories":[{"measurements":[{"groupId":"OG000","value":"1.634369451"}]}]},{"title":"EC-GC-1, MEF2C-AS2","categories":[{"measurements":[{"groupId":"OG000","value":"1.753288691"}]}]},{"title":"EC-GC-1, ENSG00000285801","categories":[{"measurements":[{"groupId":"OG000","value":"1.440844025"}]}]},{"title":"EC-GC-1, FAM228B","categories":[{"measurements":[{"groupId":"OG000","value":"-1.22996414"}]}]},{"title":"EC-GC-1, GLS","categories":[{"measurements":[{"groupId":"OG000","value":"0.868999317"}]}]},{"title":"EC-GC-1, GDPD4","categories":[{"measurements":[{"groupId":"OG000","value":"-6.564026305"}]}]},{"title":"EC-GC-1, INSYN2A","categories":[{"measurements":[{"groupId":"OG000","value":"1.759769032"}]}]},{"title":"EC-GC-1, TNFRSF14","categories":[{"measurements":[{"groupId":"OG000","value":"-1.254004029"}]}]},{"title":"EC-GC-1, PRX","categories":[{"measurements":[{"groupId":"OG000","value":"-1.199880651"}]}]},{"title":"EC-GC-1, PNN","categories":[{"measurements":[{"groupId":"OG000","value":"-1.024604708"}]}]},{"title":"EC-GC-1, KCNQ1OT1","categories":[{"measurements":[{"groupId":"OG000","value":"-0.794847103"}]}]},{"title":"EC-GC-1, ACAP3","categories":[{"measurements":[{"groupId":"OG000","value":"-1.44397269"}]}]},{"title":"EC-GC-1, BASP1-AS1","categories":[{"measurements":[{"groupId":"OG000","value":"-4.83539932"}]}]},{"title":"EC-GC-1, RBFOX1","categories":[{"measurements":[{"groupId":"OG000","value":"-1.706411849"}]}]},{"title":"EC-GC-1, CCDC90B-AS1","categories":[{"measurements":[{"groupId":"OG000","value":"-1.678217382"}]}]},{"title":"EC-GC-1, ENSG00000240499","categories":[{"measurements":[{"groupId":"OG000","value":"1.514399208"}]}]},{"title":"EC-GC-1, LINC03076","categories":[{"measurements":[{"groupId":"OG000","value":"1.545248095"}]}]},{"title":"EC-GC-1, LINC01409","categories":[{"measurements":[{"groupId":"OG000","value":"-1.022992954"}]}]},{"title":"EC-GC-1, CCT4","categories":[{"measurements":[{"groupId":"OG000","value":"1.455396063"}]}]},{"title":"EC-GC-1, CDC73","categories":[{"measurements":[{"groupId":"OG000","value":"0.802691458"}]}]},{"title":"EC-GC-1, NUMA1","categories":[{"measurements":[{"groupId":"OG000","value":"-0.931923316"}]}]},{"title":"EC-GC-1, FLT4","categories":[{"measurements":[{"groupId":"OG000","value":"-0.935590968"}]}]},{"title":"EC-GC-1, PDLIM5","categories":[{"measurements":[{"groupId":"OG000","value":"0.764926487"}]}]},{"title":"EC-GC-1, SPCS3","categories":[{"measurements":[{"groupId":"OG000","value":"1.02068757"}]}]},{"title":"EC-GC-1, ENSG00000250646","categories":[{"measurements":[{"groupId":"OG000","value":"1.917331079"}]}]},{"title":"EC-GC-1, ENSG00000258168","categories":[{"measurements":[{"groupId":"OG000","value":"1.083991656"}]}]},{"title":"EC-GC-1, ST8SIA4","categories":[{"measurements":[{"groupId":"OG000","value":"0.901071433"}]}]},{"title":"EC-GC-1, BCL2L1-AS1","categories":[{"measurements":[{"groupId":"OG000","value":"1.262413164"}]}]},{"title":"EC-GC-1, NRSN2-AS1","categories":[{"measurements":[{"groupId":"OG000","value":"-1.275348201"}]}]},{"title":"EC-GC-1, STARD13-AS","categories":[{"measurements":[{"groupId":"OG000","value":"1.148054491"}]}]},{"title":"EC-GC-1, CFLAR-AS1","categories":[{"measurements":[{"groupId":"OG000","value":"1.168941896"}]}]},{"title":"EC-GC-1, PRKAR1A","categories":[{"measurements":[{"groupId":"OG000","value":"1.257792414"}]}]},{"title":"EC-GC-1, ENSG00000226239","categories":[{"measurements":[{"groupId":"OG000","value":"1.126077043"}]}]},{"title":"EC-GC-1, CTNNA3","categories":[{"measurements":[{"groupId":"OG000","value":"-1.819759686"}]}]},{"title":"EC-GC-1, KCNK5","categories":[{"measurements":[{"groupId":"OG000","value":"-2.491597199"}]}]},{"title":"EC-GC-1, ESR2","categories":[{"measurements":[{"groupId":"OG000","value":"1.071576206"}]}]},{"title":"EC-GC-1, SLC25A46","categories":[{"measurements":[{"groupId":"OG000","value":"1.062235788"}]}]},{"title":"EC-GC-1, REV3L","categories":[{"measurements":[{"groupId":"OG000","value":"0.792446528"}]}]},{"title":"EC-GC-1, ZC2HC1C","categories":[{"measurements":[{"groupId":"OG000","value":"2.027909336"}]}]},{"title":"EC-GC-1, ENSG00000279686","categories":[{"measurements":[{"groupId":"OG000","value":"-1.453758633"}]}]},{"title":"EC-GC-1, ACER1","categories":[{"measurements":[{"groupId":"OG000","value":"-5.256214457"}]}]},{"title":"EC-GC-1, MALRD1","categories":[{"measurements":[{"groupId":"OG000","value":"-2.36001857"}]}]},{"title":"EC-GC-1, RRBP1","categories":[{"measurements":[{"groupId":"OG000","value":"-0.837125744"}]}]},{"title":"EC-GC-1, ZNF451-AS1","categories":[{"measurements":[{"groupId":"OG000","value":"1.853753635"}]}]},{"title":"EC-GC-1, SHANK2","categories":[{"measurements":[{"groupId":"OG000","value":"-1.481833304"}]}]},{"title":"EC-GC-1, ENSG00000248388","categories":[{"measurements":[{"groupId":"OG000","value":"2.196067138"}]}]},{"title":"EC-GC-1, KPNA5","categories":[{"measurements":[{"groupId":"OG000","value":"0.936135624"}]}]},{"title":"EC-GC-1, APPAT","categories":[{"measurements":[{"groupId":"OG000","value":"-1.750949862"}]}]},{"title":"EC-GC-1, PCNT","categories":[{"measurements":[{"groupId":"OG000","value":"-0.932423432"}]}]},{"title":"EC-GC-1, ENSG00000233848","categories":[{"measurements":[{"groupId":"OG000","value":"2.752498803"}]}]},{"title":"EC-GC-1, MORF4L2","categories":[{"measurements":[{"groupId":"OG000","value":"1.28059543"}]}]},{"title":"EC-GC-1, ENSG00000236283","categories":[{"measurements":[{"groupId":"OG000","value":"-1.572597604"}]}]},{"title":"EC-GC-1, SNRNP70","categories":[{"measurements":[{"groupId":"OG000","value":"-0.883484114"}]}]},{"title":"EC-GC-1, EXD3","categories":[{"measurements":[{"groupId":"OG000","value":"-0.805539835"}]}]},{"title":"EC-GC-1, CNTNAP5","categories":[{"measurements":[{"groupId":"OG000","value":"-2.392758482"}]}]},{"title":"EC-GC-1, CASR","categories":[{"measurements":[{"groupId":"OG000","value":"-2.323412555"}]}]},{"title":"EC-GC-1, ENSG00000285692","categories":[{"measurements":[{"groupId":"OG000","value":"1.124516569"}]}]},{"title":"EC-GC-1, WDR81","categories":[{"measurements":[{"groupId":"OG000","value":"-2.102548546"}]}]},{"title":"EC-GC-1, ZNF160","categories":[{"measurements":[{"groupId":"OG000","value":"-0.907890266"}]}]},{"title":"EC-GC-1, CA12","categories":[{"measurements":[{"groupId":"OG000","value":"-1.63720477"}]}]},{"title":"EC-GC-1, MAPK8IP3","categories":[{"measurements":[{"groupId":"OG000","value":"-0.998528168"}]}]},{"title":"EC-GC-1, ABTB3","categories":[{"measurements":[{"groupId":"OG000","value":"-2.945080572"}]}]},{"title":"EC-GC-1, CHORDC1","categories":[{"measurements":[{"groupId":"OG000","value":"1.047593755"}]}]},{"title":"EC-GC-1, FREM1","categories":[{"measurements":[{"groupId":"OG000","value":"-1.948982139"}]}]},{"title":"EC-GC-1, FXYD6-AS1","categories":[{"measurements":[{"groupId":"OG000","value":"2.22442108"}]}]},{"title":"EC-GC-1, SPACA6","categories":[{"measurements":[{"groupId":"OG000","value":"-1.045439073"}]}]},{"title":"EC-GC-1, AGBL1","categories":[{"measurements":[{"groupId":"OG000","value":"-2.851170905"}]}]},{"title":"EC-GC-2, NES","categories":[{"measurements":[{"groupId":"OG000","value":"-2.451444521"}]}]},{"title":"EC-GC-2, ADARB2","categories":[{"measurements":[{"groupId":"OG000","value":"-3.212266234"}]}]},{"title":"EC-GC-2, SERPINB9","categories":[{"measurements":[{"groupId":"OG000","value":"2.315559798"}]}]},{"title":"EC-GC-2, ENSG00000274422","categories":[{"measurements":[{"groupId":"OG000","value":"-2.329265154"}]}]},{"title":"EC-GC-2, BTNL9","categories":[{"measurements":[{"groupId":"OG000","value":"-2.01168798"}]}]},{"title":"EC-GC-2, CPEB2","categories":[{"measurements":[{"groupId":"OG000","value":"1.51543417"}]}]},{"title":"EC-GC-2, TBX2","categories":[{"measurements":[{"groupId":"OG000","value":"-2.604511077"}]}]},{"title":"EC-GC-2, ENSG00000290560","categories":[{"measurements":[{"groupId":"OG000","value":"2.378813977"}]}]},{"title":"EC-GC-2, CFAP54","categories":[{"measurements":[{"groupId":"OG000","value":"1.988387042"}]}]},{"title":"EC-GC-2, ABI3BP","categories":[{"measurements":[{"groupId":"OG000","value":"1.57362138"}]}]},{"title":"EC-GC-2, SPACA6","categories":[{"measurements":[{"groupId":"OG000","value":"-1.724379529"}]}]},{"title":"EC-GC-2, ADAMTSL2","categories":[{"measurements":[{"groupId":"OG000","value":"-2.009897896"}]}]},{"title":"EC-GC-2, LZTS1","categories":[{"measurements":[{"groupId":"OG000","value":"-2.659531511"}]}]},{"title":"EC-GC-2, ENSG00000285744","categories":[{"measurements":[{"groupId":"OG000","value":"1.889210245"}]}]},{"title":"EC-GC-2, ENSG00000225689","categories":[{"measurements":[{"groupId":"OG000","value":"-1.414674941"}]}]},{"title":"EC-GC-2, LUZP2","categories":[{"measurements":[{"groupId":"OG000","value":"-4.384000321"}]}]},{"title":"EC-GC-2, NCKAP5","categories":[{"measurements":[{"groupId":"OG000","value":"-1.592351284"}]}]},{"title":"EC-GC-2, FAT1","categories":[{"measurements":[{"groupId":"OG000","value":"-1.855192898"}]}]},{"title":"NKC-NKT, AGBL4","categories":[{"measurements":[{"groupId":"OG000","value":"-2.145446805"}]}]},{"title":"NKC-NKT, TFEC","categories":[{"measurements":[{"groupId":"OG000","value":"1.989578132"}]}]},{"title":"NKC-NKT, ENSG00000254186","categories":[{"measurements":[{"groupId":"OG000","value":"-2.913048038"}]}]},{"title":"NKC-NKT, PDE10A","categories":[{"measurements":[{"groupId":"OG000","value":"-2.170777761"}]}]},{"title":"NKC-NKT, SHANK2","categories":[{"measurements":[{"groupId":"OG000","value":"-2.431773845"}]}]},{"title":"PEC, RGS6","categories":[{"measurements":[{"groupId":"OG000","value":"-3.331377896"}]}]},{"title":"PEC, AHNAK","categories":[{"measurements":[{"groupId":"OG000","value":"-1.645129407"}]}]},{"title":"PT-2, LRRC4C","categories":[{"measurements":[{"groupId":"OG000","value":"-2.167101922"}]}]},{"title":"PT-2, DSCAM","categories":[{"measurements":[{"groupId":"OG000","value":"-3.104786855"}]}]},{"title":"PT-2, RCN3","categories":[{"measurements":[{"groupId":"OG000","value":"-1.636040003"}]}]}]},{"type":"SECONDARY","title":"Change in Glomerular Basement Membrane Width (Kidney Biopsy)","description":"Change in glomerular basement membrane width assessed in kidney biopsy from baseline (week 0) to end of treatment (week 52) is presented.","populationDescription":"Full analysis set included all participants randomly assigned to trial treatment and who took at least 1 dose of trial product. Overall Number participants analyzed = number of participants with available data for particular timepoint, for the respective arms.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Nanometer (nm)","timeFrame":"Baseline (week 0), End of treatment (week 52)","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Participants received once-weekly (OW) subcutaneous (s. c.) injection of semaglutide for 52 weeks. Participants received a dose of 0.25 milligrams (mg) from week 0 to week 4, then the dose was increased to 0.5 mg from week 4 to week 8. From week 8 to week 52, the dosage was 1.0 mg."},{"id":"OG001","title":"Placebo","description":"Participants received once-weekly (OW) subcutaneous injection (s. c.) of placebo matched for semaglutide for 52 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-72.67","spread":"96.60"},{"groupId":"OG001","value":"-8.66","spread":"206.35"}]}]}]},{"type":"SECONDARY","title":"Change in Apparent Diffusion Coefficient (ADC) (Cortex) (MRI)","description":"Change in apparent diffusion coefficient in cortex assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.","populationDescription":"Full analysis set included all participants randomly assigned to trial treatment and who took at least 1 dose of trial product. Overall number of participants analyzed= FAS. Number Analyzed= number of participants with available data for particular timepoint, for the respective arms.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of ADC (cortex)","timeFrame":"Baseline (week 0), End of treatment (week 52)","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Participants received once-weekly (OW) subcutaneous (s. c.) injection of semaglutide for 52 weeks. Participants received a dose of 0.25 milligrams (mg) from week 0 to week 4, then the dose was increased to 0.5 mg from week 4 to week 8. From week 8 to week 52, the dosage was 1.0 mg."},{"id":"OG001","title":"Placebo","description":"Participants received once-weekly (OW) subcutaneous injection (s. c.) of placebo matched for semaglutide for 52 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"35"}]}],"classes":[{"title":"Bilateral cortex","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"6.56"},{"groupId":"OG001","value":"0.94","spread":"11.40"}]}]},{"title":"Left cortex","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"8.50"},{"groupId":"OG001","value":"0.96","spread":"10.48"}]}]},{"title":"Right cortex","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"6.70"},{"groupId":"OG001","value":"0.93","spread":"12.12"}]}]}]},{"type":"SECONDARY","title":"Change in Apparent Diffusion Coefficient (ADC) (Medulla) (MRI)","description":"Change in apparent diffusion coefficient in medulla assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.","populationDescription":"Full analysis set included all participants randomly assigned to trial treatment and who took at least 1 dose of trial product. Overall number of participants analyzed= FAS. Number Analyzed= number of participants with available data for particular timepoint, for the respective arms.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of ADC (medulla)","timeFrame":"Baseline (week 0), End of treatment (week 52)","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Participants received once-weekly (OW) subcutaneous (s. c.) injection of semaglutide for 52 weeks. Participants received a dose of 0.25 milligrams (mg) from week 0 to week 4, then the dose was increased to 0.5 mg from week 4 to week 8. From week 8 to week 52, the dosage was 1.0 mg."},{"id":"OG001","title":"Placebo","description":"Participants received once-weekly (OW) subcutaneous injection (s. c.) of placebo matched for semaglutide for 52 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"35"}]}],"classes":[{"title":"Bilateral medulla","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"8.90"},{"groupId":"OG001","value":"0.94","spread":"13.51"}]}]},{"title":"Left medulla","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"9.51"},{"groupId":"OG001","value":"0.95","spread":"13.41"}]}]},{"title":"Right medulla","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"10.00"},{"groupId":"OG001","value":"0.93","spread":"13.94"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Renal Artery Resistive Index (RARI) (MRI)","description":"Change in renal arterial resistive index assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented. RARI measures the preservation of blood flow in renal arteries throughout the cardiac cycle and is therefore a measure for resistance of blood flow within the renal arteries. It serves as an indicator of kidney vascular health and potential arterial stiffness or obstruction. It is prognostic for primary cardiovascular and renal events in type 2 diabetes, where a lower RARI predicts a lower rate of events. RARI is calculated by relating the difference between blood flow at maximum velocity during the cardiac contraction phase (peak systolic velocity, PSV) and the speed at the end of the relaxation phase, at the point of minimal velocity (end diastolic velocity, EDV) with PSV, i.e., RARI = (PSV-EDV)/PSV.","populationDescription":"Full analysis set included all participants randomly assigned to trial treatment and who took at least 1 dose of trial product. Overall number of participants analyzed= FAS. Number Analyzed= number of participants with available data for particular timepoint, for the respective arms.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of RARI","timeFrame":"Baseline (week 0), End of treatment (week 52)","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Participants received once-weekly (OW) subcutaneous (s. c.) injection of semaglutide for 52 weeks. Participants received a dose of 0.25 milligrams (mg) from week 0 to week 4, then the dose was increased to 0.5 mg from week 4 to week 8. From week 8 to week 52, the dosage was 1.0 mg."},{"id":"OG001","title":"Placebo","description":"Participants received once-weekly (OW) subcutaneous injection (s. c.) of placebo matched for semaglutide for 52 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"35"}]}],"classes":[{"title":"Bilateral renalartery","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"7.00"},{"groupId":"OG001","value":"1.01","spread":"6.13"}]}]},{"title":"Right renalartery","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"8.38"},{"groupId":"OG001","value":"1.01","spread":"8.62"}]}]},{"title":"Left renalartery","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"7.44"},{"groupId":"OG001","value":"1.01","spread":"6.43"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Arterial Flow (MRI)","description":"Change in mean arterial flow assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.","populationDescription":"Full analysis set included all participants randomly assigned to trial treatment and who took at least 1 dose of trial product. Overall number of participants analyzed= FAS. Number Analyzed= number of participants with available data for particular timepoint, for the respective arms.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of mean arterial flow","timeFrame":"Baseline (week 0), End of treatment (week 52)","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Participants received once-weekly (OW) subcutaneous (s. c.) injection of semaglutide for 52 weeks. Participants received a dose of 0.25 milligrams (mg) from week 0 to week 4, then the dose was increased to 0.5 mg from week 4 to week 8. From week 8 to week 52, the dosage was 1.0 mg."},{"id":"OG001","title":"Placebo","description":"Participants received once-weekly (OW) subcutaneous injection (s. c.) of placebo matched for semaglutide for 52 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"35"}]}],"classes":[{"title":"Bilateral renalartery","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"24.96"},{"groupId":"OG001","value":"0.96","spread":"25.06"}]}]},{"title":"Right renalartery","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"30.21"},{"groupId":"OG001","value":"0.95","spread":"29.09"}]}]},{"title":"Left renalartery","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"25.06"},{"groupId":"OG001","value":"0.98","spread":"27.38"}]}]}]},{"type":"SECONDARY","title":"Change in Natriuresis (Urinary Sodium Excretion) (Urinalysis)","description":"Change in natriuresis (urinary sodium excretion) (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.","populationDescription":"Full analysis set included all participants randomly assigned to trial treatment and who took at least 1 dose of trial product. Overall Number participants analyzed = number of participants with available data for particular timepoint, for the respective arms.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Millimoles per day (mmol/day)","timeFrame":"Baseline (week 0), End of treatment (week 52)","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Participants received once-weekly (OW) subcutaneous (s. c.) injection of semaglutide for 52 weeks. Participants received a dose of 0.25 milligrams (mg) from week 0 to week 4, then the dose was increased to 0.5 mg from week 4 to week 8. From week 8 to week 52, the dosage was 1.0 mg."},{"id":"OG001","title":"Placebo","description":"Participants received once-weekly (OW) subcutaneous injection (s. c.) of placebo matched for semaglutide for 52 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.3","spread":"71.3"},{"groupId":"OG001","value":"-26.9","spread":"85.2"}]}]}]},{"type":"SECONDARY","title":"Change in Albumin Excretion Rate (Urinalysis)","description":"Change in albumin excretion rate (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.","populationDescription":"Full analysis set included all participants randomly assigned to trial treatment and who took at least 1 dose of trial product. Overall Number participants analyzed = number of participants with available data for particular timepoint, for the respective arms.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Milligrams per day (mg/d)","timeFrame":"Baseline (week 0), End of treatment (week 52)","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Participants received once-weekly (OW) subcutaneous (s. c.) injection of semaglutide for 52 weeks. Participants received a dose of 0.25 milligrams (mg) from week 0 to week 4, then the dose was increased to 0.5 mg from week 4 to week 8. From week 8 to week 52, the dosage was 1.0 mg."},{"id":"OG001","title":"Placebo","description":"Participants received once-weekly (OW) subcutaneous injection (s. c.) of placebo matched for semaglutide for 52 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-81.9","spread":"708.8"},{"groupId":"OG001","value":"-233.2","spread":"964.8"}]}]}]},{"type":"SECONDARY","title":"Change in Kidney Function (Creatinine Clearance) (Urinalysis)","description":"Change in kidney function (creatinine clearance) (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.","populationDescription":"Full analysis set included all participants randomly assigned to trial treatment and who took at least 1 dose of trial product. Overall Number participants analyzed = number of participants with available data for particular timepoint, for the respective arms.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Milliliter per minute","timeFrame":"Baseline (week 0), End of treatment (week 52)","groups":[{"id":"OG000","title":"Semaglutide 1.0 mg","description":"Participants received once-weekly (OW) subcutaneous (s. c.) injection of semaglutide for 52 weeks. Participants received a dose of 0.25 milligrams (mg) from week 0 to week 4, then the dose was increased to 0.5 mg from week 4 to week 8. From week 8 to week 52, the dosage was 1.0 mg."},{"id":"OG001","title":"Placebo","description":"Participants received once-weekly (OW) subcutaneous injection (s. c.) of placebo matched for semaglutide for 52 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"26.6"},{"groupId":"OG001","value":"-12.6","spread":"34.2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to week 57","description":"Safety analysis set- all participants randomly assigned to trial treatment \\& who take at least 1 dose of trial product. All presented AEs are treatment emergent adverse events (TEAEs). A TEAE was defined as an AE with onset in all observed data points from first date of study product until permanent discontinuation of treatment. A participant died after discontinuing study by physician decision hence was counted in 'physician decision' category in 'Participant Flow' in semaglutide arm.","eventGroups":[{"id":"EG000","title":"Semaglutide 1.0 mg","description":"Participants received once-weekly (OW) subcutaneous (s. c.) injection of semaglutide for 52 weeks. Participants received a dose of 0.25 milligrams (mg) from week 0 to week 4, then the dose was increased to 0.5 mg from week 4 to week 8. From week 8 to week 52, the dosage was 1.0 mg.","deathsNumAffected":2,"deathsNumAtRisk":71,"seriousNumAffected":14,"seriousNumAtRisk":71,"otherNumAffected":15,"otherNumAtRisk":71},{"id":"EG001","title":"Placebo","description":"Participants received once-weekly (OW) subcutaneous injection (s. c.) of placebo matched for semaglutide for 52 weeks.","deathsNumAffected":1,"deathsNumAtRisk":35,"seriousNumAffected":5,"seriousNumAtRisk":35,"otherNumAffected":11,"otherNumAtRisk":35}],"seriousEvents":[{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Anger","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Arteriosclerosis coronary artery","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Coronary artery stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":35}]},{"term":"End stage renal disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Haemorrhagic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Osteitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":35}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Pancreatic carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":35}]},{"term":"Peripheral vascular disorder","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Renal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Skin ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":35}]},{"term":"Spinal cord injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":35}]}],"otherEvents":[{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":71},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35}]},{"term":"Diabetic retinopathy","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":71},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":35}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":71},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":35}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":71},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":35}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":71},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":35}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":71},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":35}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property."},"pointOfContact":{"title":"Clinical Reporting Office (2834)","organization":"Novo Nordisk A/S","email":"clinicaltrials@novonordisk.com","phone":"(+1) 866-867-7178"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2022-04-21","uploadDate":"2025-11-20T13:22","filename":"Prot_000.pdf","size":1266384},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2025-03-21","uploadDate":"2025-11-20T13:22","filename":"SAP_001.pdf","size":491812}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2025-12-03","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"},{"id":"D051436","term":"Renal Insufficiency, Chronic"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D051437","term":"Renal Insufficiency"},{"id":"D007674","term":"Kidney Diseases"},{"id":"D014570","term":"Urologic Diseases"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D052801","term":"Male Urogenital Diseases"},{"id":"D002908","term":"Chronic Disease"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"C000591245","term":"semaglutide"}]}},"hasResults":true}